| Website | medimmune.com/ven... |
| Phone | (301) 398-4624 |
| Employees | |
| Description | Venture Capital |
MedImmune Ventures is a wholly owned venture capital fund within the AstraZeneca/MedImmune group of companies. It was created in 2002 to leverage MedImmune’s expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies.
MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies focused on discovering and developing human therapeutics. MedImmune Ventures primarily seeks to invest in areas of strategic interest to Astra Zeneca and MedImmune, including infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system disorders, and gastrointestinal disease. We are modality agnostic, investing in biologics, small molecules, and vaccines.
| Company | Date | Round | Size | Participants |
| Arginetix | 11/09 | Series B | $4.6M | 5 |
| Virdante Pharmaceuticals | 10/09 | Series A | $48M | 5 |
| VaxInnate | 6/09 | Series D | $30M | 7 |
| Applied Genetics Technologies Corporation | 6/09 | Series C | $11.8M | 3 |
| NKT Therapeutics | 3/09 | Series A | $8M | 2 |
| Rib-X Pharmaceuticals | 1/09 | Unattributed | $25M | 8 |
| Hydra Biosciences | 1/09 | Series D | $22M | 1 |
| Arginetix | 10/08 | Angel | $2.3M | 4 |
| LigoCyte Pharmaceuticals | 4/08 | Series B | $28M | 4 |
| BrainCells | 3/08 | Series B | $30M | 6 |
| Applied Genetics Technologies Corporation | 11/03 | Series B | $27M | 4 |
